- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00337376
A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers
January 13, 2014 updated by: Maysa Abu-Khalaf, Yale University
A Phase I Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Solid Cancers
Rapamycin is a drug that has been approved by the Food and Drug Administration (government) for use in patients receiving a kidney transplant to prevent the patient's body from rejecting the transplanted kidney.
It has shown antitumor effects in the laboratory, but has not been approved at this time for the treatment of cancer.
Abraxane is a new form of chemotherapy that has been approved by the Food and Drug Administration for the treatment of metastatic breast cancer, and is a promising drug that is being evaluated in clinical trials for treatment of other cancers.
This is a phase I study designed to find out if different doses of Rapamycin, when combined with Abraxane, are safe and well tolerated.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale Comprehensive Cancer Center at Yale University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must have histologically-confirmed advanced solid tumors.
- For patients with metastatic breast cancer, there will be no restriction on prior therapy. For patients with other advanced solid tumors, they must be refractory to standard therapy or for which no curative standard therapy exists, to be considered. Metastatic disease, if present, should not be progressing so as to require palliative treatment within 4 weeks of enrollment based on clinical assessment by the investigator.
- Development of new lesions or an increase in preexisting lesions on bone scintigraphy, CT, MRI or by physical examination. Patients in whom the sole criterion for progression is an increase in a biochemical marker, e.g., carcinoembryonic antigen (CEA), or an increase in symptoms, are not eligible.
- No radiotherapy, treatment with cytotoxic agents, or treatment with biologic agents within the 4 weeks prior to beginning treatment on this study (6 weeks for mitomycin or nitrosoureas). At least 2 weeks must have elapsed from any prior surgery or hormonal therapy. Patients must have fully recovered from the acute toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment). Patients with persisting, stable chronic toxicities from prior treatment ≤ grade 1 are eligible.
- Age ≥18 years.
- ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).
- Life expectancy of greater than 3 months.
- Patients must have normal organ and marrow function as defined below:
Hemoglobin ≥ 9 g/dL leukocytes ≥3,000/mcL absolute neutrophil count ≥1,500/mcL platelets ≥100,000/mcL total bilirubin within normal institutional limits AST(SGOT)/ALT(SGPT)2.5 X institutional upper limit of normal creatinine within 1.5 x ULN OR creatinine clearance ≥50 mL/min/1.73 m² for patients with creatinine levels ≥1.5 ULN.
- Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and must have a negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial. Pregnant and nursing patients are excluded because the effects of the combination of Abraxane and Rapamycin on a fetus or nursing child are unknown. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Sexually active men must also use appropriate contraception method and should not father a child while receiving therapy during this study.
- Ability to understand and the willingness to sign a written informed consent document.
- Fasting serum cholesterol <350 mg/d L and triglycerides < 400 mg/ d L.
- Biopsy is required but patients or physicians may opt out of this part of the trial if sufficient justification is provided. Justification must be provided to the PI in writing indicating excessive physical risk or psychological trauma if biopsy is taken
Exclusion Criteria:
- Patients must be 4 weeks from chemotherapy or radiotherapy and have recovered from any adverse events
- Patients may not be receiving any other investigational agents.
- Patients with known active brain metastases. Patients must have completed definitive treatment for brain metastases, at least 4 weeks prior to first dose on this study, and off steroids for at least 2 weeks, with stable or regressing CNS lesions by MRI or CT scan, and no evidence of new lesions.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study.
- Peripheral neuropathy ≥ Grade 2
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant women are excluded from this study because the investigational agents may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated.
- HIV-positive patients are ineligible because these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy and the potential pharmacokinetic interaction between antiretroviral therapy and the investigational agents.
- All herbal and alternative medications should be discontinued while on study, these include but not limited to: Hydrastis canadensis (goldenseal), Uncaria tomentosa (cat's claw) Echinacea angustifolia
- Use of any of these medications within 1 week, prior to the first dose of treatment: cyclosporine, diltiazem, ketoconazole, rifampin, fluconazole, delavirdine, nicardipine, pioglitazone and sulfonamides, erythromycin, clarithromycin, itraconazole, metoclopramide, nevirapine, Phenobarbital, phenytoin, indinavir fosamprenavir, ritonavir, efavirenz, nefazadone, and St. John's wort.
- Consumption of grapefruit juice is prohibited during the study.
- Requirement for treatment with warfarin (Coumadin), immunosuppressive agents or chronic steroids
- Prior therapy with rapamycin, rapamycin analogs or experimental agents targeting mTOR
- Prior Abraxane therapy
- Active infection or treatment for systemic infections within 14 days of enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
Other Names:
intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the safety, dose-limiting toxicities, and maximum tolerated dose of weekly oral Rapamycin in combination with weekly intravenous Abraxane for three out of four consecutive weeks in patients with advanced solid cancers.
Time Frame: upon completion of study
|
upon completion of study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
to determine if weekly administration of Rapamycin changes the pharmacokinetic profile of weekly Abraxane
Time Frame: upon completion of study
|
upon completion of study
|
To determine pre and post therapy changes in p70S6K in peripheral mononuclear cells in patients treated with oral Rapamycin and Abraxane
Time Frame: Upon completion of study
|
Upon completion of study
|
To evaluate changes in the phosphorylation of p70S6K on tumor tissue and to determine the correlation with phosphorylation of p70S6K in the peripheral mononuclear cells, in patients who give consent to pre and post tumor biopsies
Time Frame: upon completion of study
|
upon completion of study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Maysa Abu-Khalaf, M.D., Yale University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2006
Primary Completion (Actual)
July 1, 2010
Study Completion (Actual)
July 1, 2010
Study Registration Dates
First Submitted
June 13, 2006
First Submitted That Met QC Criteria
June 13, 2006
First Posted (Estimate)
June 15, 2006
Study Record Updates
Last Update Posted (Estimate)
January 14, 2014
Last Update Submitted That Met QC Criteria
January 13, 2014
Last Verified
January 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Paclitaxel
- Albumin-Bound Paclitaxel
- Sirolimus
Other Study ID Numbers
- 0511000860
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Cancers
-
Agenus Inc.CompletedAdvanced Solid Cancers | Advanced Solid Cancers Refractory to PD-1United States
-
Bristol-Myers SquibbActive, not recruitingAdvanced Solid CancersUnited States, Canada
-
Polaris GroupTerminated
-
Chong Kun Dang PharmaceuticalCompletedAdvanced Solid CancersKorea, Republic of
-
M.D. Anderson Cancer CenterCompleted
-
M.D. Anderson Cancer CenterGlaxoSmithKline; National Comprehensive Cancer NetworkCompletedSolid Tumors | Advanced CancersUnited States
-
M.D. Anderson Cancer CenterCompletedSolid Tumors | Advanced CancersUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingMetastatic Solid Tumor Cancers | Locally Advanced Solid Tumor CancersUnited States
-
Deciphera Pharmaceuticals LLCTerminatedMetastatic Solid Tumors | Locally Advanced Tumors | Cancers With MET Genomic Alterations | Cancers With TRK Genomic AlterationsUnited States
-
Semafore PharmaceuticalsSignalRX Pharmaceuticals, Inc.CompletedCancer | Advanced or Metastatic Solid Tumors | Solid CancersUnited States
Clinical Trials on Rapamune
-
University Medicine GreifswaldCompletedHypercholesterolemia | Pharmacokinetics | Immunosuppression | Drug InteractionsGermany
-
University of NottinghamUniversity of OxfordRecruitingMuscle Atrophy | Age-Related SarcopeniaUnited Kingdom
-
St. Joseph's Healthcare HamiltonWithdrawn
-
University of ChicagoRecruitingPulmonary Fibrosis | COVID-19 Pneumonia | Long COVIDUnited States
-
National Eye Institute (NEI)Completed
-
University of California, San FranciscoWithdrawnSevere Combined Immunodeficiency | Stem Cell Transplant | Transplacental Maternal EngraftmentUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
PfizerCompletedRenal TransplantationArgentina
-
Fundacio PuigvertMinistry of Health, SpainCompleted
-
Medical University of South CarolinaWyeth is now a wholly owned subsidiary of PfizerCompleted